Skip to main content

Advertisement

SpringerLink
Log in

Establishment and characterization of NCC-SS3-C1: a novel patient-derived cell line of synovial sarcoma

  • Cell Line
  • Published:
Human Cell Aims and scope Submit manuscript

Abstract

Synovial sarcoma is a rare malignancy of mesenchymal origin, characterized by a chromosomal translocation, t(X;18) (p11.2;q11.2). Wide surgical resection with radiation and cytotoxic chemotherapy is established as a standard treatment; however synovial sarcoma remains a high-grade sarcoma with poor prognosis, and novel anti-cancer agents and immunological approaches are currently being developed. The patient-derived cell line is a critical tool for basic and pre-clinical research. However, only a few patient-derived synovial sarcoma cell lines are publicly available from cell banks. Thus, the aim of this study was to establish and characterize a novel cell line for synovial sarcoma. Using a surgically resected tumor tissue from a 48-year-old female patient, we successfully established a cell line, named NCC-SS3-C1. NCC-SS3-C1 cells harbor an SS18-SSX1 fusion gene and exhibit moderate growth, spheroid formation, and invasion. We examined a range of proliferation-inhibiting effects of small molecule anti-cancer compounds, including FDA-approved anti-cancer drugs, using NCC-SS3-C1 cells, and identified anti-cancer drugs which inhibited the proliferation of NCC-SS3-C1 cells at the low concentration. We concluded that NCC-SS3-C1 would be a useful tool for basic and pre-clinical synovial sarcoma research.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Ferrari A, Gronchi A, Casanova M, et al. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer. 2004;101:627–34.

    Article  Google Scholar 

  2. Vlenterie M, Ho VK, Kaal SE, Vlenterie R, Haas R, van der Graaf WT. Age as an independent prognostic factor for survival of localised synovial sarcoma patients. Br J Cancer. 2015;113:1602–6.

    Article  Google Scholar 

  3. Guillou L, Benhattar J, Bonichon F, et al. Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J Clin Oncol. 2004;22:4040–50.

    Article  Google Scholar 

  4. Sultan I, Rodriguez-Galindo C, Saab R, Yasir S, Casanova M, Ferrari A. Comparing children and adults with synovial sarcoma in the Surveillance, epidemiology, and end results program, 1983 to 2005: an analysis of 1268 patients. Cancer. 2009;115:3537–47.

    Article  Google Scholar 

  5. Guadagnolo BA, Zagars GK, Ballo MT, et al. Long-term outcomes for synovial sarcoma treated with conservation surgery and radiotherapy. Int J Radiat Oncol Biol Phys. 2007;69:1173–80.

    Article  Google Scholar 

  6. Fletcher CDM, Bridge JA, Hogendoorn P, Mertens F. WHO classification of tumours of soft tissue and bone. Fourth Edition edn. Geneva: WHO Press; 2013.

    Google Scholar 

  7. Jones KB, Barrott JJ, Xie M, et al. The impact of chromosomal translocation locus and fusion oncogene coding sequence in synovial sarcomagenesis. Oncogene. 2016;35:5021–32.

    Article  CAS  Google Scholar 

  8. Haldar M, Hancock JD, Coffin CM, Lessnick SL, Capecchi MR. A conditional mouse model of synovial sarcoma: insights into a myogenic origin. Cancer Cell. 2007;11:375–88.

    Article  CAS  Google Scholar 

  9. Vlenterie M, Hillebrandt-Roeffen MH, Flucke UE, et al. Next generation sequencing in synovial sarcoma reveals novel gene mutations. Oncotarget. 2015;6:34680–90.

    Article  Google Scholar 

  10. Oda Y, Sakamoto A, Satio T, Kawauchi S, Iwamoto Y, Tsuneyoshi M. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma. Mod Pathol. 2000;13:994–1004.

    Article  CAS  Google Scholar 

  11. Lagarde P, Przybyl J, Brulard C, et al. Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas. J Clin Oncol. 2013;31:608–15.

    Article  CAS  Google Scholar 

  12. Przybyl J, Sciot R, Wozniak A, et al. Metastatic potential is determined early in synovial sarcoma development and reflected by tumor molecular features. Int J Biochem Cell Biol. 2014;53:505–13.

    Article  CAS  Google Scholar 

  13. Stacchiotti S, Van Tine BA. Synovial Sarcoma: Current Concepts and Future Perspectives. J Clin Oncol. 2018;36:180–7.

    Article  CAS  Google Scholar 

  14. Bairoch A. The cellosaurus, a cell-line knowledge resource. J Biomol Tech. 2018;29:25–38.

    Article  Google Scholar 

  15. Kito F, Oyama R, Takai Y, et al. Establishment and characterization of the NCC-SS1-C1 synovial sarcoma cell line. Hum Cell. 2018;31:167–74.

    Article  CAS  Google Scholar 

  16. Oyama R, Kito F, Sakumoto M, et al. Establishment and proteomic characterization of a novel synovial sarcoma cell line, NCC-SS2-C1. Vitro Cell Dev Biol Animal. 2018;54:392–9.

    Article  CAS  Google Scholar 

  17. Okimoto RA, Wu W, Nanjo S, et al. CIC-DUX4 oncoprotein drives sarcoma metastasis and tumorigenesis via distinct regulatory programs. J Clin Investig. 2019;129:3401–6.

    Article  Google Scholar 

  18. Nath S, Devi GR. Three-dimensional culture systems in cancer research: Focus on tumor spheroid model. Pharmacol Ther. 2016;163:94–108.

    Article  CAS  Google Scholar 

  19. Adams J, Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest. 2004;22:304–11.

    Article  CAS  Google Scholar 

  20. Perez M, Peinado-Serrano J, Garcia-Heredia JM, et al. Efficacy of bortezomib in sarcomas with high levels of MAP17 (PDZK1IP1). Oncotarget. 2016;7:67033–46.

    Article  Google Scholar 

  21. Teicher BA, Polley E, Kunkel M, et al. Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microrna expression. Mol Cancer Ther. 2015;14:2452–62.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Drs. F Nakatani, E Kobayashi, S Fukushima, M Nakagawa, T Komatsubara, M Saito, and C Sato, (Department of Musculoskeletal Oncology, National Cancer Center Hospital), and Drs. T Shibayama, and H Tanaka (Department of Diagnosis Pathology, National Cancer Center Hospital), for providing tumor tissue specimens from the surgically resected tumor. We greatly appreciate the technical assistance by Mr. T. Ono and K. Tanoue. We would like to thank Editage (www.editage.jp) for English-language editing and their constructive comments during manuscript preparation. This research was financially supported by the National Cancer Center Research and Development Fund (grant nos. 29-A-2).

Author information

Authors and Affiliations

  1. Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Yuki Yoshimatsu, Rei Noguchi, Ryuto Tsuchiya, Akane Sei & Tadashi Kondo

  2. Department of Orthopaedic Surgery, Graduate School of Medicine, Chiba University, 1-8-1, Inohana, Chuo-ku, Chiba, 260-8670, Japan

    Ryuto Tsuchiya

  3. Department of Musculoskeletal Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Jun Sugaya, Shintaro Iwata & Akira Kawai

  4. Department of Diagnosis Pathology, 0045, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-, Japan

    Akihiko Yoshida

Authors
  1. Yuki Yoshimatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rei Noguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ryuto Tsuchiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Akane Sei
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jun Sugaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shintaro Iwata
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Akihiko Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Akira Kawai
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tadashi Kondo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tadashi Kondo.

Ethics declarations

Conflicts of interest

The authors declare that there are no conflicts of interest.

Consent for publication

Consent for publication was provided by the patient. The ethical committee of National Cancer Center approved the use of clinical materials for this study with the approved number of 2004–050.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (XLSX 12 kb)

Supplementary file2 (XLSX 25 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yoshimatsu, Y., Noguchi, R., Tsuchiya, R. et al. Establishment and characterization of NCC-SS3-C1: a novel patient-derived cell line of synovial sarcoma. Human Cell 33, 877–885 (2020). https://doi.org/10.1007/s13577-020-00354-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13577-020-00354-6

Keywords

Search

Navigation